Im Jong-yoon: "No Plans to Sell Hanmi Science Shares"

[Image source=Yonhap News]

원본보기 아이콘

Jong-yoon Lim, President of Hanmi Pharm, and Jong-hoon Lim, CEO of Hanmi Precision Chemical, drew a clear line by stating, “We have never considered selling Hanmi Science shares, and we have no plans to sell them in the future.”

On the 25th, President Jong-yoon Lim said in a statement, “Joo-hyun Lim, President of Hanmi Pharm, publicly released an official statement on the 24th asking OCI to buy shares and transfer the holding company’s management rights entirely, and to place the shares that are not even hers under protective custody, while also requesting that the shares of the two brothers, Jong-yoon Lim and Jong-hoon Lim, be protected for three years,” adding, “I hope she clarifies the intention behind this incomprehensible statement.”

President Lim pointed out, “I do not understand why such a contextless proposal is suddenly being made in a situation where it has been partially acknowledged that the management rights of the 50-year-old Hanmi Pharm Group were secretly handed over to OCI by the company’s major shareholders in January, and that the merger was to resolve inheritance tax issues.”

He also stated, “On the 22nd, Chairman Dong-guk Shin expressed great concern and regret from the beginning about some major shareholders conducting transactions that significantly affected the company’s governance and management rights to solve personal economic issues such as inheritance tax. However, due to the long-standing relationship between the late chairman and his family, he waited for an amicable resolution among the family,” adding, “But since the corporate value continues to decline and shareholder value is being damaged, he expressed support for the two brothers, Jong-yoon Lim and Jong-hoon Lim, who can carry on the late chairman’s will and enhance corporate and shareholder value.”

He emphasized, “I cannot help but ask whether this is because the confidence in the ‘OCI-Hanmi merger’ has been shaken and the mind has become impatient.”

Meanwhile, the two brothers, Jong-yoon Lim and Jong-hoon Lim, presented the ‘NEW Hanmi Pharm Future Vision’ at a press conference on the 21st, promising that if they win at this shareholders’ meeting, they will continue the tradition of Hanmi as a pioneer in new drug development, achieve a net profit of 1 trillion KRW within five years through attracting 1 trillion KRW in investment, and enter the top tier with a market capitalization of 50 trillion KRW. They pledged to prioritize restoring the currently undervalued stock price and enhancing shareholder value.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.